评估非靶向活检在炎症性肠病结直肠肿瘤检测中效用的试验中期分析
炎症性肠病累及结直肠者结直肠癌风险较一般人群高1.5至2倍,指南推荐强化监测结肠镜。部分学会主张在靶向活检和/或切除可见病变外,广泛行非靶向(随机)活检筛查「不可见」肿瘤病变,但缺乏高质量对照数据;非靶向活检肿瘤检出率低(0.1%-0.2%),而近期法国大型队列报告其仍可识别高达20%的肿瘤灶,但主要见于合并其他主要结直肠癌危险因素者。本试验中期分析旨在评估非靶向活检在炎症性肠病结直肠肿瘤检测中的效用。
要点
- 炎症性肠病累及结直肠者结直肠癌风险较年龄和性别匹配的一般人群高1.5至2倍。
- 部分学会主张在靶向活检和/或切除可见病变外,广泛行非靶向活检以筛查不可见肿瘤病变。
- 非靶向活检肿瘤检出率低(0.1%-0.2%),且缺乏高质量对照数据支持该做法。
核心结论
- 原文为试验中期分析,旨在评估非靶向活检在炎症性肠病结直肠肿瘤检测中的效用,未报告中期分析结论。
研究设计与样本
- 原文为试验的中期分析,评估非靶向活检在炎症性肠病结直肠肿瘤检测中的效用,未报告样本量。
主要发现
- 炎症性肠病累及结直肠者结直肠癌风险较年龄和性别匹配的一般人群高1.5至2倍。
- 非靶向活检的肿瘤检出率为0.1%-0.2%。
- 近期法国大型队列研究报告非靶向活检仍可识别高达20%的肿瘤灶,但主要见于合并其他主要结直肠癌危险因素者。
关键数值与推荐
- 部分学会主张在靶向活检和/或切除可见病变外,广泛行非靶向活检以筛查不可见肿瘤病变。
- 原文指出缺乏高质量对照数据支持非靶向活检做法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persons with inflammatory bowel disease (IBD) affecting the colorectum (cIBD) have a 1.5- to 2-fold higher risk of developing colorectal cancer (CRC) relative to age- and sex-matched members of the general population.1 Intensive surveillance colonoscopy is recommended in this population to detect and treat early neoplastic lesions before they evolve to incurable cancers.2 Some societies advocate for widespread non-targeted ("random") biopsies throughout the colorectum to screen for "invisible" neoplastic lesions, in addition to targeted biopsies and/or resection of visible lesions.2 Despite the theoretical value of non-targeted biopsies in this setting, there are no high-quality, controlled data to support this practice. In addition to adding significant time and costs to colonoscopy screening, extensive biopsy sampling may also increase the risk of colorectal bleeding and bowel perforation, particularly in elderly patients and those receiving anticoagulant/antiplatelet therapies. With the widespread adoption of disease-modifying biologic and small molecule therapies,3 mucosal healing as a treatment end point,4 high-definition endoscopes,5 and endoscopy quality standards,6 as well as reports of very low neoplasia yield for non-targeted biopsies (0.1%-0.2% of biopsies),7 many experts have started to question the value of non-targeted biopsies as an adjunct for neoplasia surveillance in persons with cIBD.8 However, a recent large French cohort study reported that non-targeted biopsies still identify up to 20% of all neoplastic foci in persons with cIBD,9 albeit primarily in individuals with other major CRC risk factors.
引用
- Murthy SK, Bernstein CN, Nguyen GC, et al. Interim Analysis of a Trial Evaluating the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2023. PMID: 38122957. doi:10.1016/j.cgh.2023.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。